NCT00411645
Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients
PHASE3
COMPLETED
NCT00411645
INTERVENTIONAL
A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants.
The purpose of this research study is to investigate whether or not maribavir is safe and effective for preventing CMV disease when taken by mouth for up to 12 weeks in patients who have had a stem cell transplant.
Inclusion Criteria:
* Allogeneic stem cell transplant recipient
* Recipient or donor CMV seropositive
* Have transplant engraftment
* Able to swallow tablets
Exclusion Criteria:
* CMV organ disease
* HIV infection
* Use of other anti-CMV therapy post-transplant
Cytomegalovirus Infections
- PREVENTION
-
- Type: DRUG
- Name: maribavir
- Description: 100 mg twice daily for up to 12 weeks
- Arm Group Labels: A
-
- Type: OTHER
- Name: placebo
- Description: twice daily for up to 12 weeks
- Arm Group Labels: B
- Shire